HHLR ADVISORS, LTD.
13F Holdings and Portfolio Analysis
Zhang Lei 2019 Q2 13F holdings, quarterly changes, portfolio value trend and position weight distribution.
HHLR ADVISORS, LTD. Overview
HHLR ADVISORS, LTD. held 43 stocks in 2019 Q2, with total market value around $4.47B.
HHLR ADVISORS, LTD.'s top five holdings in 2019 Q2: BeOne Medicines AG(ONC) 12.30%, JD.com, Inc.(JD) 10.67%, TAL Education Group(TAL) 9.72%, iQIYI, Inc.(IQ) 6.70%, CHINA BIOLOGIC PRODS HLDGS I(CBPO) 5.86%.
- Portfolio Value
- $4.47B
- Current Holdings
- 43 stocks
- New / Increased
- 13 / 6
- Reduced / Exited
- 1 / 0
Current Holdings
| 1 | BeOne Medicines AGONC | 0.55 | 12.30% | 4.44 - | $123.95 | $316.42 +155.28% | $140.26 | 0.00 | 0.75 | +$0.78B+125.60% | Held |
| 2 | JD.com, Inc.JD | 0.48 | 10.67% | 15.75 +4.72% | $30.29 | $33.07 +9.18% | $21.35 | +0.71 | 0.75 | +$0.18B+54.88% | Increased |
| 3 | TAL Education GroupTAL | 0.43 | 9.72% | 11.41 - | $38.10 | $11.09 -70.89% | $29.92 | 0.00 | 0.75 | -$0.21B-62.94% | Held |
| 4 | iQIYI, Inc.IQ | 0.30 | 6.70% | 14.51 +15.55% | $20.65 | $2.03 -90.17% | $22.77 | +1.95 | 0.75 | -$0.30B-91.09% | Increased |
| 5 | CHINA BIOLOGIC PRODS HLDGS ICBPO | 0.26 | 5.86% | 2.75 - | $95.30 | - | $75.91 | 0.00 | 0.75 | +$0.05B+25.54% | Held |
| 6 | Alibaba Group Holding LimitedBABA | 0.24 | 5.35% | 1.41 - | $169.45 | $125.39 -26.00% | $137.07 | 0.00 | 0.75 | -$0.02B-8.52% | Held |
| 7 | Meta Platforms, Inc.META | 0.23 | 5.09% | 1.18 - | $193.00 | $612.96 +217.60% | $166.69 | 0.00 | 0.50 | +$0.53B+267.72% | Held |
| 8 | New Oriental Education & Technology Group Inc.EDU | 0.16 | 3.68% | 1.70 +60704.79% | $96.58 | $56.83 -41.16% | $96.57 | +1.70 | 0.50 | -$0.07B-41.15% | Increased |
| 9 | PDD HOLDINGS INC COMMON STOCKPDD | 0.15 | 3.32% | 7.20 +129.81% | $20.63 | $88.14 +327.27% | $21.88 | +4.07 | 0.75 | +$0.48B+302.91% | Increased |
| 10 | 58 COM INCWUBA | 0.15 | 3.28% | 2.36 | $62.17 | - | $62.17 | +2.36 | 0.25 | $0.00B0.00% | New |
| 11 | Sea LimitedSE | 0.14 | 3.19% | 4.30 - | $33.22 | $90.53 +172.52% | $23.52 | 0.00 | 0.50 | +$0.29B+284.91% | Held |
| 12 | BLUEPRINT MEDICINES CORPBPMC | 0.14 | 3.16% | 1.50 - | $94.33 | - | $55.09 | 0.00 | 0.75 | +$0.06B+71.23% | Held |
| 13 | Mondelez International, Inc.MDLZ | 0.14 | 3.07% | 2.55 -15.52% | $53.90 | $62.41 +15.79% | $40.03 | -0.47 | 0.75 | +$0.06B+55.91% | Reduced |
| 14 | Bilibili Inc.BILI | 0.13 | 2.94% | 8.09 +134.35% | $16.27 | $27.05 +66.26% | $16.24 | +4.64 | 0.75 | +$0.09B+66.57% | Increased |
| 15 | FibroGen, Inc.FGEN | 0.12 | 2.75% | 2.72 +36.00% | $45.18 | $10.38 -77.03% | $45.99 | +0.72 | 0.75 | -$0.10B-77.43% | Increased |
| 16 | TESLA INC COMTSLA | 0.12 | 2.60% | 0.52 | $223.46 | $423.76 +89.63% | $223.46 | +0.52 | 0.25 | +$0.10B+89.63% | New |
| 17 | MELCO RESORTS AND ENTMNT LTD ADRMLCO | 0.10 | 2.13% | 4.40 - | $21.72 | - | $22.56 | 0.00 | 0.75 | -$0.00B-3.73% | Held |
| 18 | ENSTAR GROUP LIMITEDESGR | 0.09 | 2.12% | 0.54 - | $174.28 | $22.00 -87.38% | $174.00 | 0.00 | 0.50 | -$0.08B-87.36% | Held |
| 19 | Apellis Pharmaceuticals, Inc.APLS | 0.07 | 1.46% | 2.58 - | $25.34 | $24.52 -3.24% | $14.05 | 0.00 | 0.75 | +$0.03B+74.57% | Held |
| 20 | Snap Inc.SNAP | 0.06 | 1.43% | 4.47 | $14.30 | $7.65 -46.50% | $14.30 | +4.47 | 0.25 | -$0.03B-46.50% | New |
| 21 | BridgeBio Pharma, Inc.BBIO | 0.06 | 1.42% | 2.35 | $26.97 | $54.92 +103.63% | $26.97 | +2.35 | 0.25 | +$0.07B+103.63% | New |
| 22 | MYOKARDIA INCMYOK | 0.05 | 1.09% | 0.98 - | $50.14 | - | $49.24 | 0.00 | 0.75 | +$0.00B+1.83% | Held |
| 23 | BRIGHT SCHOLAR ED HLDGS LTDBEDU | 0.04 | 0.81% | 3.99 - | $9.06 | - | $9.21 | 0.00 | 0.75 | -$0.00B-1.63% | Held |
| 24 | MOMO INCMOMO | 0.03 | 0.78% | 0.97 | $35.80 | $236.00 +559.22% | $35.80 | +0.97 | 0.25 | +$0.19B+559.22% | New |
| 25 | LINE CORPLN | 0.03 | 0.76% | 1.21 - | $28.14 | $21.35 -24.13% | $34.11 | 0.00 | 0.75 | -$0.02B-37.41% | Held |
Showing 1-25 of 43
"Holding Period (yrs)" is the latest uninterrupted holding duration, calculated by dividing continuous reported quarters by 4.
Cost basis is an estimate and can differ materially from the actual cost, especially in edge cases.
Cost basis estimate: from the latest uninterrupted holding period, new or increased shares are added to the cost pool at the report price; reductions remove shares at the then-average cost. Example: buy 100 shares at $10 in Q1 and add 50 shares at $16 in Q2, estimated cost basis is (100 x 10 + 50 x 16) / 150 = $12 per share.
Return shows estimated dollar return on top and percentage return below. It uses current price when available, otherwise report price.
Portfolio Visuals
Track portfolio value, position weights and Top 10 history.